BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar Sells 75,000 Shares of Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar sold 75,000 shares of the business’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $33.57, for a total transaction of $2,517,750.00. Following the transaction, the chief executive officer now directly owns 5,023,447 shares of the company’s stock, valued at approximately $168,637,115.79. This represents a 1.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Neil Kumar also recently made the following trade(s):

• On Wednesday, February 19th, Neil Kumar sold 31,543 shares of BridgeBio Pharma stock. The stock was sold at an average price of $36.14, for a total value of $1,139,964.02.
• On Tuesday, January 28th, Neil Kumar sold 326,932 shares of BridgeBio Pharma stock. The shares were sold at an average price of $36.29, for a total value of $11,864,362.28.

BridgeBio Pharma Trading Up 2.6 %

Shares of BBIO opened at $34.30 on Friday. The stock has a market cap of $6.52 billion, a PE ratio of -12.04 and a beta of 1.07. BridgeBio Pharma, Inc. has a 1 year low of $21.62 and a 1 year high of $39.47. The stock has a 50 day simple moving average of $32.51 and a 200-day simple moving average of $28.21.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The business had revenue of $5.88 million during the quarter, compared to analysts’ expectations of $4.04 million. On average, sell-side analysts forecast that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on BBIO shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $95.00 price target on shares of BridgeBio Pharma in a report on Friday, February 21st. HC Wainwright reaffirmed a “buy” rating and set a $49.00 target price on shares of BridgeBio Pharma in a research report on Thursday, February 13th. Bank of America increased their price target on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. Scotiabank boosted their price objective on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Friday, February 21st. Finally, Citigroup increased their target price on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the company a “buy” rating in a research note on Friday, February 21st. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $51.67.

Institutional Investors Weigh In On BridgeBio Pharma

Hedge funds have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC grew its stake in BridgeBio Pharma by 85.8% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock worth $28,000 after buying an additional 472 shares during the last quarter. Itau Unibanco Holding S.A. acquired a new position in shares of BridgeBio Pharma in the 4th quarter worth approximately $41,000. Sterling Capital Management LLC grew its position in BridgeBio Pharma by 554.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,787 shares of the company’s stock worth $49,000 after acquiring an additional 1,514 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in BridgeBio Pharma during the 4th quarter valued at $109,000. Finally, Advisors Asset Management Inc. raised its position in BridgeBio Pharma by 56.1% in the 3rd quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company’s stock valued at $117,000 after purchasing an additional 1,645 shares during the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.